Prasugrel formindskede eksponeringen for hydroxybupropion, en CYP2B6- medieret metabolit af bupropion, med 23% hos raske forsøgspersoner.
In healthy subjects, prasugrel decreased exposure to hydroxybupropion, a CYP2B6-mediated metabolite of bupropion, by 23%.